Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zaoui, P.
Right arrow Articles by Hakim, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zaoui, P.
Right arrow Articles by Hakim, R. M.

Journal of the American Society of Nephrology, Vol 4, 1711-1718, Copyright © 1994 by American Society of Nephrology

REGULAR ARTICLES

The effects of the dialysis membrane on cytokine release

P Zaoui and RM Hakim
Service de Nephrologie, Universite de Grenoble, France.

The immune response requires the coordinated release of a network of cytokines including interleukin-1 (IL-1), tumor necrosis factor (TNF), and IL-2. The potential role of the dialysis membrane on the elaboration of these cytokines by peripheral blood mononuclear cells (PBMNC) harvested from hemodialysis patients was investigated in a prospective crossover study. Eight hemodialysis patients, chronically dialyzed with a biocompatible membrane, were sequentially dialyzed for 2 wk with new cuprophane membranes (Phase I), 2 wk with a low-flux, low- complement-activating membrane (Phase II), and then switched back for a further 2 wk of dialysis with a cuprophane membrane (Phase III). At the end of 2 wk of exposure to the cuprophane membrane, during both Phase I and Phase III, the ability of PBMNC to elaborate IL-1 beta, tumor necrosis factor-alpha, and IL-2, as well as soluble IL-2 receptors, in response to phytohemagglutinin was significantly reduced compared with their respective levels at the beginning of the phase; dialysis with a biocompatible membrane increased these levels, and at the end of 2 wk, the response of the PBMNC to phytohemagglutinin was close to that in normal controls. These findings may explain some of the conflicting results in the measurement of cytokine levels in hemodialysis patients and may have clinical implications.


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
P. Meier, F. Spertini, E. Blanc, and M. Burnier
Oxidized Low-Density Lipoproteins Activate CD4+ T Cell Apoptosis in Patients with End-Stage Renal Disease through Fas Engagement
J. Am. Soc. Nephrol., January 1, 2007; 18(1): 331 - 342.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
B. Memoli, G. Grandaliano, M. Soccio, L. Postiglione, B. Guida, V. Bisesti, P. Esposito, A. Procino, D. Marrone, A. Michael, et al.
In Vivo Modulation of Soluble "Antagonistic" IL-6 Receptor Synthesis and Release in ESRD
J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1099 - 1107.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
F. F. Hou, H. Ren, W. F. Owen Jr, Z. J. Guo, P. Y. Chen, A. M. Schmidt, T. Miyata, and X. Zhang
Enhanced Expression of Receptor for Advanced Glycation End Products in Chronic Kidney Disease
J. Am. Soc. Nephrol., July 1, 2004; 15(7): 1889 - 1896.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. A. KAYSEN
The Microinflammatory State in Uremia: Causes and Potential Consequences
J. Am. Soc. Nephrol., July 1, 2001; 12(7): 1549 - 1557.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
K. A. HERZIG, D. M. PURDIE, W. CHANG, A. M. BROWN, C. M. HAWLEY, S. B. CAMPBELL, J. M. STURTEVANT, N. M. ISBEL, D. L. NICOL, and D. W. JOHNSON
Is C-Reactive Protein a Useful Predictor of Outcome in Peritoneal Dialysis Patients?
J. Am. Soc. Nephrol., April 1, 2001; 12(4): 814 - 821.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
F. Locatelli, J. Bommer, G. M. London, A. Martin-Malo, C. Wanner, M. Yaqoob, and C. Zoccali
Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment
Nephrol. Dial. Transplant., March 1, 2001; 16(3): 459 - 468.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
Y. Le Meur, V. Lorgeot, J.-C. Aldigier, J. Wijdenes, C. Leroux-Robert, and V. Praloran
Whole blood production of monocytic cytokines (IL-1{beta}, IL-6, TNF-{alpha}, sIL-6R, IL-1Ra) in haemodialysed patients
Nephrol. Dial. Transplant., October 1, 1999; 14(10): 2420 - 2426.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
B. MEMOLI, L. MARZANO, V. BISESTI, M. ANDREUCCI, and B. GUIDA
Hemodialysis-Related Lymphomononuclear Release of Interleukin-12 in Patients with End-Stage Renal Disease
J. Am. Soc. Nephrol., October 1, 1999; 10(10): 2171 - 2176.
[Abstract] [Full Text]

Home page
 Nephrol Dial TransplantHome page
T. Vraetz, T. H. Ittel, M. G. van Mackelenbergh, P. C. Heinrich, H. G. Sieberth, and L. Graeve
Regulation of {beta}2-microglobulin expression in different human cell lines by proinflammatory cytokines
Nephrol. Dial. Transplant., September 1, 1999; 14(9): 2137 - 2143.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673